This is the first case of ICI-induced multiple endocrinopathies following the administration of PD-L1 inhibitor avelumab, presenting with simultaneously diagnosed thyrotoxicosis due to thyroiditis and adrenal insufficiency due to hypophysitis. The gene discussed is CD274; the disease is thyroiditis.